NCT04591275View on ClinicalTrials.gov

Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .

PHASE3CompletedINTERVENTIONAL
Enrollment

278

Participants

Timeline

Start Date

March 31, 2021

Primary Completion Date

November 1, 2024

Study Completion Date

November 1, 2024

Conditions
Postmenopausal Osteoporosis
Interventions
DRUG

CMAB807 Injection

mAb targeting RANKL, human monoclonal antibody targeting RANKL

DRUG

Prolia®

mAb targeting RANKL, human monoclonal antibody targeting RANKL

Trial Locations (1)

Unknown

Peking Union Medical College Hosptial, Beijing

All Listed Sponsors
lead

Shanghai Biomabs Pharmaceutical Co., Ltd.

INDUSTRY

NCT04591275 - Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® . | Biotech Hunter | Biotech Hunter